PHARMING GROUP Stock Euronext Amsterdam
Stocks
NL0000377018
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Euronext Amsterdam
|
||
| - EUR | - |
|
| 09-13 | Pharming Group Obtains US FDA Nod for Rare Primary Immunodeficiency Drug Joenja | MT |
| 09-11 | Pharming Receives Fda Approval for Joenja as First Treatment for Children with Apds in the U S | CI |
| Market Cap | 744M 648M 612M 556M 1.04B 71.35B 1.05B 7.31B 2.82B 36.28B 2.8B 2.73B 117B | P/E 2026 * |
33.7x | P/E 2027 * | 25x |
|---|---|---|---|---|---|
| Enterprise Value | 697M 607M 573M 521M 976M 66.87B 980M 6.86B 2.65B 34.01B 2.62B 2.56B 109B | EV / Sales 2026 * |
1.82x | EV / Sales 2027 * | 1.63x |
| Free-Float |
98.05% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: PHARMING GROUP
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 2025-03-03 | |
Kenneth Lynard
DFI | Director of Finance/CFO | 58 | 2025-09-30 |
Anurag Relan
CTO | Chief Tech/Sci/R&D Officer | 54 | 2021-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Barbara Yanni
BRD | Director/Board Member | 71 | 2020-12-10 |
Mark Pykett
BRD | Director/Board Member | 62 | 2020-12-10 |
| Director/Board Member | 60 | 2021-05-18 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.04% | +3.34% | +53.32% | +100.52% | 1,028B | |
| -0.09% | +1.66% | +53.24% | +66.45% | 651B | |
| -0.02% | +2.66% | +18.65% | +71.97% | 466B | |
| -1.22% | +3.66% | +36.44% | +38.32% | 346B | |
| -0.79% | +2.73% | +19.03% | +25.08% | 266B | |
| +0.58% | +6.76% | +11.13% | +16.52% | 259B | |
| +1.55% | +2.20% | +35.12% | +45.91% | 208B | |
| +0.79% | +1.84% | -28.27% | -56.71% | 191B | |
| -0.52% | +4.45% | +31.57% | +98.11% | 186B | |
| Average | +0.04% | +3.26% | +25.58% | +45.13% | 400.19B | |
| Weighted average by Cap. | -0.04% | +3.09% | +35.12% | +61.45% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 383M 334M 315M 286M 536M 36.76B 539M 3.77B 1.46B 18.69B 1.44B 1.41B 60.13B | 417M 363M 343M 312M 584M 40.01B 586M 4.1B 1.58B 20.35B 1.57B 1.53B 65.45B |
| Net income | 22.11M 19.25M 18.17M 16.51M 30.93M 2.12B 31.07M 217M 83.94M 1.08B 83.05M 81.21M 3.47B | 33.62M 29.27M 27.63M 25.1M 47.02M 3.22B 47.24M 330M 128M 1.64B 126M 123M 5.27B |
| Net Debt | -46.69M -40.65M -38.37M -34.86M -65.31M -4.48B -65.6M -459M -177M -2.28B -175M -171M -7.32B | -62.12M -54.08M -51.05M -46.38M -86.88M -5.96B -87.28M -611M -236M -3.03B -233M -228M -9.74B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
